Moderna to Report Third Quarter 2024 Financial Results on Thursday, November 7, 2024
Moderna (NASDAQ:MRNA) has announced its plans to report third quarter 2024 financial results on Thursday, November 7, 2024.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Moderna (NASDAQ:MRNA) has announced its plans to report third quarter 2024 financial results on Thursday, November 7, 2024. The company will host a live conference call and webcast at 8:00 a.m. ET to discuss the results and provide a corporate update. Investors can access the live webcast through the 'Events and Presentations' section of Moderna's website. The archived webcast will be available approximately two hours after the conference call and will remain accessible for one year following the event. This announcement serves as a notice to shareholders and interested parties about the upcoming financial disclosure and opportunity to gain insights into Moderna's recent performance and future outlook.
Details
News Market Reaction – MRNA
The recorded move for MRNA in the trading session of this news was -4.59%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, MA / ACCESSWIRE / October 17, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, November 7, 2024 to report its third quarter 2024 financial results, and provide a corporate update.
A live webcast of the call will be available under "Events and Presentations" in the Investors section of the Moderna website.
Webcast: https://investors.modernatx.com
The archived webcast will be available on Moderna's website approximately two hours after the conference call and will be available for one year following the call.
About Moderna
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.
Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com
SOURCE: Moderna, Inc.
View the original press release on accesswire.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.